Eli Lilly (LLY) EPS (Weighted Average and Diluted) Growth (1y) (2013 - 2026)
Eli Lilly (LLY) EPS (Weighted Average and Diluted) Growth (1y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Weighted Avg. Diluted) Growth (1y) (Qtr) |
| 1 |
Gsk |
96,436,181.12 Bn |
96,436,176.16 Bn |
7.76 Bn |
- |
| 2 |
Eli Lilly |
1,017.30 Bn |
1,012.01 Bn |
16.22 Bn |
169.93% |
| 3 |
Johnson & Johnson |
579.61 Bn |
557.55 Bn |
15.96 Bn |
-52.86% |
| 4 |
AbbVie |
402.30 Bn |
392.96 Bn |
10.78 Bn |
-45.83% |
| 5 |
Merck |
294.24 Bn |
288.59 Bn |
12.09 Bn |
-185.57% |
| 6 |
Amgen |
191.82 Bn |
179.78 Bn |
5.87 Bn |
4.37% |
| 7 |
Gilead Sciences |
155.93 Bn |
148.21 Bn |
5.52 Bn |
54.81% |
| 8 |
Pfizer |
149.05 Bn |
136.28 Bn |
-1.21 Bn |
-9.62% |
| 9 |
Bristol Myers Squibb |
116.33 Bn |
105.88 Bn |
8.07 Bn |
9.17% |
| 10 |
Novartis Ag |
112.59 Bn |
111.90 Bn |
- |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
169.93% |
| Dec 31, 2025 |
51.43% |
| Sep 30, 2025 |
480.37% |
| Jun 30, 2025 |
91.77% |
| Mar 31, 2025 |
23.39% |
| Dec 31, 2024 |
101.65% |
| Sep 30, 2024 |
1,883.33% |
| Jun 30, 2024 |
68.21% |
| Mar 31, 2024 |
66.44% |
| Dec 31, 2023 |
13.08% |
| Sep 30, 2023 |
-103.73% |
| Jun 30, 2023 |
85.71% |
| Mar 31, 2023 |
-29.05% |
| Dec 31, 2022 |
13.23% |
| Sep 30, 2022 |
31.97% |
| Jun 30, 2022 |
-31.37% |
| Mar 31, 2022 |
40.94% |
| Dec 31, 2021 |
-18.53% |
| Sep 30, 2021 |
-8.27% |
| Jun 30, 2021 |
-1.29% |
